We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-20.02%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.95B
AUM Growth
-$629M
Cap. Flow
+$37M
Cap. Flow %
1.9%
Top 10 Hldgs %
47.94%
Holding
79
New
8
Increased
5
Reduced
2
Closed
5

Top Buys

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$67.8M
2
APLS
Apellis Pharmaceuticals
APLS
+$57.6M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$49.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$36.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$26.1M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$139M
2
ITOS
iTeos Therapeutics
ITOS
+$41.9M
3
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$4.88M
4
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$4.88M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 96.15%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
26
DELISTED
Amicus Therapeutics
FOLD
$22M 1.13%
2,325,000
– –
BLU
27
DELISTED
BELLUS Health Inc.
BLU
$22M 1.13%
3,200,000
– –
GOSS icon
28
Gossamer Bio
GOSS
$83.2M
$21.4M 1.1%
2,462,358
– –
KNTE
29
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$20.8M 1.07%
1,847,559
– –
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$20.7M 1.06%
1,121,327
– –
PNT
31
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$19.9M 1.02%
2,500,000
– –
FATE icon
32
Fate Therapeutics
FATE
$324M
$19.4M 1%
500,000
– –
GHRS icon
33
GH Research
GHRS
$1.97B
$18.5M 0.95%
1,013,399
– –
XENE icon
34
Xenon Pharmaceuticals
XENE
$6.6B
$18.3M 0.94%
600,000
– –
NRIX icon
35
Nurix Therapeutics
NRIX
$2.4B
$17.2M 0.88%
1,224,892
– –
NUVL
36
DELISTED
Nuvalent
NUVL
$16.8M 0.86%
1,210,192
– –
RARE icon
37
Ultragenyx Pharmaceutical
RARE
$2.88B
$14.5M 0.75%
200,000
– –
MIST icon
38
Milestone Pharmaceuticals
MIST
$148M
$14.4M 0.74%
2,238,861
– –
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
$11.8M 0.61%
1,189,943
– –
AKRO
40
DELISTED
Akero Therapeutics
AKRO
$11.8M 0.61%
831,495
– –
CNTA
41
DELISTED
Centessa Pharmaceuticals
CNTA
$11.3M 0.58%
1,251,137
– –
CGEM icon
42
Cullinan Oncology
CGEM
$1.09B
$11.2M 0.58%
1,074,082
– –
PRTA icon
43
Prothena Corp
PRTA
$453M
$11M 0.56%
300,000
– –
TPTX
44
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$10.7M 0.55%
+400,000
New +$13.4M
THRX
45
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$10.3M 0.53%
892,057
– –
TSVT
46
DELISTED
2seventy bio
TSVT
$7.84M 0.4%
+459,836
New +$7.8M
NGM
47
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$7.63M 0.39%
500,000
– –
BCEL
48
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.98M 0.36%
2,202,333
– –
SLDB icon
49
Solid Biosciences
SLDB
$858M
$6.4M 0.33%
355,735
+143,888
+68% +$2.54M
RAIN
50
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$5.96M 0.31%
1,175,000
– –
1
2
3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Boxer Capital held 79 positions worth $1.95B, down 24% from $2.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital's Q1 2022 filing shows 8 new, 5 increased, 2 reduced and 5 closed positions. Its largest new stake was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $139M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 87% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q1 2022 buy was Prometheus Biosciences, Inc. Common Stock: 1,714,000 shares worth $64.7M.
  • Boxer Capital added most to Acadia Pharmaceuticals in Q1 2022, an estimated $26.1M increase.
  • Boxer Capital's biggest Q1 2022 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $139M.
  • Boxer Capital fully exited Jiya Acquisition Corp. Class A Common Stock in Q1 2022, selling an estimated $4.88M.
  • Boxer Capital's ten largest holdings make up 48% of its $1.95B portfolio in Q1 2022.
  • Boxer Capital opened 8 new positions and closed 5 in Q1 2022.
  • Boxer Capital's portfolio value fell 24% quarter-over-quarter to $1.95B.

Based on Boxer Capital's 13F filing for Q1 2022, filed 16 May 2022.